US-based digital therapeutics company Propeller Health has raised $20m in its series D round led by drug delivery company Aptar Pharma.
Hikma Ventures, 3M Ventures and SR One, respective corporate venturing units of pharmaceutical firm Hikma, manufacturing company 3M and healthcare group GlaxoSmithKline, also took part in the round, as did Safeguard Scientifics and Social Capital.
Founded in 2010, Propeller Health is working on a digital therapy platform for patients suffering from chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease. It relies on machine learning to recommend a personalised treatment.
The round will support Propeller’s pipeline of digital therapeutics and additional connected devices for the treatment of chronic respiratory disease. Propeller will also begin to develop digital medicines for new therapeutic areas.
Propeller and Aptar Pharma have also entered a strategic partnership to work with pharmaceutical firms and co-develop and co-market digital medicines across therapeutic areas.
The round takes its total raised to more than $60m, having previously closed a $21.5m series C round in 2016 that featured 3M Ventures, SR One and Hikma Ventures as well as Safeguard Scientifics and Social Capital.
Propeller also secured a strategic investment from Well Ventures, the corporate venturing arm of pharmacy retail chain Walgreens, in June 2014, though details of the deal remain undisclosed.